Evolent Health, Inc. (NYSE:EVH) Shares Sold by Farallon Capital Management LLC

Farallon Capital Management LLC trimmed its holdings in Evolent Health, Inc. (NYSE:EVH - Free Report) by 97.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,000 shares of the technology company's stock after selling 625,000 shares during the period. Farallon Capital Management LLC's holdings in Evolent Health were worth $158,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in EVH. Vanguard Group Inc. lifted its position in shares of Evolent Health by 2.4% in the fourth quarter. Vanguard Group Inc. now owns 11,171,199 shares of the technology company's stock worth $125,676,000 after buying an additional 259,781 shares in the last quarter. Engaged Capital LLC increased its stake in Evolent Health by 35.5% during the fourth quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company's stock worth $60,804,000 after acquiring an additional 1,415,300 shares during the last quarter. Cadian Capital Management LP bought a new stake in Evolent Health during the fourth quarter worth approximately $58,781,000. Dimensional Fund Advisors LP increased its stake in Evolent Health by 19.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,897,443 shares of the technology company's stock worth $32,595,000 after acquiring an additional 466,225 shares during the last quarter. Finally, Boston Partners increased its stake in Evolent Health by 92.0% during the fourth quarter. Boston Partners now owns 2,444,006 shares of the technology company's stock worth $27,097,000 after acquiring an additional 1,171,304 shares during the last quarter.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, President Daniel Joseph Mccarthy bought 11,040 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were purchased at an average price of $9.01 per share, for a total transaction of $99,470.40. Following the transaction, the president now directly owns 389,004 shares of the company's stock, valued at approximately $3,504,926.04. This represents a 2.92% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Seth Blackley bought 55,225 shares of the firm's stock in a transaction dated Thursday, March 6th. The shares were acquired at an average price of $9.01 per share, for a total transaction of $497,577.25. Following the transaction, the chief executive officer now directly owns 762,217 shares in the company, valued at approximately $6,867,575.17. This represents a 7.81% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 74,000 shares of company stock worth $666,315. Insiders own 1.40% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on EVH shares. Truist Financial reduced their price objective on Evolent Health from $15.00 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th. Canaccord Genuity Group cut their target price on Evolent Health from $23.00 to $16.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. UBS Group upped their target price on Evolent Health from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Friday. JPMorgan Chase & Co. cut their target price on Evolent Health from $13.00 to $12.00 and set an "overweight" rating on the stock in a research note on Monday, March 10th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $15.00 target price on shares of Evolent Health in a research note on Friday, February 21st. One investment analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $17.79.

Evolent Health Stock Performance

Shares of NYSE EVH traded up $0.22 during mid-day trading on Monday, hitting $9.27. The stock had a trading volume of 5,271,448 shares, compared to its average volume of 2,394,349. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04. The company has a 50 day moving average of $9.62 and a two-hundred day moving average of $11.37. Evolent Health, Inc. has a twelve month low of $8.35 and a twelve month high of $33.63. The firm has a market cap of $1.08 billion, a PE ratio of -11.30 and a beta of 1.04.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, May 8th. The technology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.02). The firm had revenue of $483.65 million during the quarter, compared to analyst estimates of $460.15 million. Evolent Health had a negative net margin of 2.41% and a positive return on equity of 5.73%. Evolent Health's revenue was down 24.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.34 earnings per share. Research analysts predict that Evolent Health, Inc. will post 0.08 EPS for the current fiscal year.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.